Health economic evaluation in nasopharyngeal carcinoma: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

WENG Junling ^1,2 , LUO Bingxing ^1,2 , XIAO Dunming ^1,2 ,  CHEN Yingyao ^1,2

1. School of Public Health, Fudan University, Shanghai 200032, P. R. China;
2. National Health Commission Key Laboratory of Health Technology Assessment (Fudan University), Shanghai 200032, P. R. China;

Corresponding author：

CHEN Yingyao, Email: yychen@shmu.edu.cn

Keywords：

Nasopharyngeal carcinoma; Health economic evaluation; Systematic review

DOI：

10.7507/1672-2531.202301057

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the health economic evaluation of nasopharyngeal carcinoma (NPC). Methods The PubMed, Web of Science, EMbase, CNKI, WanFang Data and CBM databases were electronically searched to collect the health economic evaluations on NPC from inception to December 18, 2022. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies. A descriptive analysis was performed. Results A total of 20 studies were included, which contained 14 about different drug combinations, 6 about chemotherapy and the comparison among intensity modulated radiotherapy, conventional radiotherapy and surgery. The results showed that for patients with recurrent, metastatic, or advanced NPC, compared with docetaxel plus cisplatin, fluorouracil plus cisplatin or docetaxel and cisplatin plus fluorouracil, gemcitabine plus cisplatin (GP) was the most economical, and compared with GP or camrelizumab plus GP, toripalimab plus GP (TGP) was more economical. For early-stage NPC, intensity modulated radiotherapy was not economical compared with conventional radiotherapy and surgery. Conclusion Current evidence shows that GP and TGP are economical and can be popularized clinically.

Citation： WENG Junling, LUO Bingxing, XIAO Dunming, CHEN Yingyao. Health economic evaluation in nasopharyngeal carcinoma: a systematic review. Chinese Journal of Evidence-Based Medicine, 2023, 23(5): 555-560. doi: 10.7507/1672-2531.202301057 Copy

1.	Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet, 2019, 394(10192): 64-80.
2.	倪良平, 刘影. DCE-MRI与DWI对鼻咽癌临床分期诊断价值的比较研究. 临床放射学杂志, 2016, 35(4): 518-522.
3.	丘敏敏. 放疗中T形口腔固定器的应用及食管癌肺受量预测模型的研究. 广州: 南方医科大学, 2021.
4.	牟文轩, 江庆华. 鼻咽癌患者经济毒性研究进展. 广西医学, 2022, 44(6): 657-661.
5.	Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force. Value Health, 2022, 25(1): 10-31.
6.	洪明晃, 麦海强, 罗东华. N_(2-3)鼻咽癌患者辅助化疗的成本效果分析. 中国肿瘤, 2000, (12): 21-22.
7.	王仁生, 韦波, 苏莉, 等. 鼻咽癌两种放射治疗方案的成本效果分析. 中华肿瘤防治杂志, 2011, 18(9): 707-709.
8.	区通源, 潘智灵. 鼻咽癌药物疗法的药效分析. 西北药学杂志, 2013, 28(1): 82-84.
9.	邓勋, 刘海燕, 王艳, 等. 康艾注射液辅助治疗鼻咽癌的临床用药评价. 实用药物与临床, 2014, 17(5): 547-550.
10.	杨珍珍. 甘氨双唑钠用于食管癌和鼻咽癌放疗增敏的Meta分析及药物经济学评价. 石家庄: 河北医科大学, 2019.
11.	刘友平, 吕星, 邹雄, 等. 单纯微创手术与调强放射治疗原发性Ⅰ期鼻咽癌的疗效比较. 癌症, 2020, 39(5): 201-212.
12.	彭迎春. GP与DP治疗晚期转移性鼻咽癌疗效及成本效果分析. 吉首: 吉首大学, 2020.
13.	邱英鹏, 孙潭霖, 赵羽西, 等. 螺旋断层放射治疗系统的成本效果分析. 中国医学装备, 2020, 17(12): 1-4.
14.	欧阳丽辉, 张顺芝, 何鸽飞, 等. 吉西他滨或氟尿嘧啶联合顺铂治疗晚期鼻咽癌的药物经济学评价. 医药导报, 2021, 40(2): 257-262.
15.	陈梦宇, 文卫平, 李健, 等. 内镜手术治疗复发性rT1-rT3期鼻咽癌基于马尔可夫模型的成本-效果分析. 中华耳鼻咽喉头颈外科杂志, 2022, 57(11): 1304-1310.
16.	Chen X, Liang W, Wan N, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol, 2019, 94: 80-85.
17.	Liao W, Huang J, Wu Q, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: a cost-effectiveness analysis. Oral Oncol, 2019, 93: 15-20.
18.	Fei Z, Xu T, Li M, et al. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol, 2020, 15(1): 230.
19.	Jin C, Zheng H, Zhan M, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol, 2020, 277(2): 577-584.
20.	Wu Q, Liao W, Huang J, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma. Oral Oncol, 2020, 103: 104588.
21.	Yang J, Han J, He J, et al. Real-world cost-effectiveness analysis of gemcitabine and cisplatin compared to docetaxel and cisplatin plus fluorouracil induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol, 2020, 10: 594756.
22.	She L, Tian K, Han J, et al. Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol, 2022, 12: 904372.
23.	Tian K, Han J, Wang Z, et al. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis. Oral Oncol, 2022, 128: 105842.
24.	Zhu Y, Liu K, Ding D, et al. Chemo-immunotherapy regimes for recurrent or metastatic nasopharyngeal carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol, 2022, 13: 858207.
25.	Li G, Xia YF, Huang YX, et al. Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: cost-effectiveness analysis. Head Neck, 2022, 44(2): 431-442.
26.	中国临床肿瘤学会指南工作委员会. 鼻咽癌诊疗指南2022. 北京:人民卫生出版社, 2022, 27: 47, 63, 69.
27.	何朝光, 傅万凯, 陈彩霞, 等. 1990和2017年中国鼻咽癌疾病负担及其趋势. 海峡预防医学杂志, 2020, 26(4): 108-110.
28.	王木清, 江文霞, 张静. 鼻咽癌门诊病例的临床特征及健康教育. 中国医药指南, 2015, 13(4): 17-19.
29.	黄志碧. 广西恶性肿瘤经济负担的现状、变动的趋势及其影响因素的研究. 南宁: 广西医科大学, 2016.

1. Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet, 2019, 394(10192): 64-80.
2. 倪良平, 刘影. DCE-MRI与DWI对鼻咽癌临床分期诊断价值的比较研究. 临床放射学杂志, 2016, 35(4): 518-522.
3. 丘敏敏. 放疗中T形口腔固定器的应用及食管癌肺受量预测模型的研究. 广州: 南方医科大学, 2021.
4. 牟文轩, 江庆华. 鼻咽癌患者经济毒性研究进展. 广西医学, 2022, 44(6): 657-661.
5. Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force. Value Health, 2022, 25(1): 10-31.
6. 洪明晃, 麦海强, 罗东华. N_(2-3)鼻咽癌患者辅助化疗的成本效果分析. 中国肿瘤, 2000, (12): 21-22.
7. 王仁生, 韦波, 苏莉, 等. 鼻咽癌两种放射治疗方案的成本效果分析. 中华肿瘤防治杂志, 2011, 18(9): 707-709.
8. 区通源, 潘智灵. 鼻咽癌药物疗法的药效分析. 西北药学杂志, 2013, 28(1): 82-84.
9. 邓勋, 刘海燕, 王艳, 等. 康艾注射液辅助治疗鼻咽癌的临床用药评价. 实用药物与临床, 2014, 17(5): 547-550.
10. 杨珍珍. 甘氨双唑钠用于食管癌和鼻咽癌放疗增敏的Meta分析及药物经济学评价. 石家庄: 河北医科大学, 2019.
11. 刘友平, 吕星, 邹雄, 等. 单纯微创手术与调强放射治疗原发性Ⅰ期鼻咽癌的疗效比较. 癌症, 2020, 39(5): 201-212.
12. 彭迎春. GP与DP治疗晚期转移性鼻咽癌疗效及成本效果分析. 吉首: 吉首大学, 2020.
13. 邱英鹏, 孙潭霖, 赵羽西, 等. 螺旋断层放射治疗系统的成本效果分析. 中国医学装备, 2020, 17(12): 1-4.
14. 欧阳丽辉, 张顺芝, 何鸽飞, 等. 吉西他滨或氟尿嘧啶联合顺铂治疗晚期鼻咽癌的药物经济学评价. 医药导报, 2021, 40(2): 257-262.
15. 陈梦宇, 文卫平, 李健, 等. 内镜手术治疗复发性rT1-rT3期鼻咽癌基于马尔可夫模型的成本-效果分析. 中华耳鼻咽喉头颈外科杂志, 2022, 57(11): 1304-1310.
16. Chen X, Liang W, Wan N, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol, 2019, 94: 80-85.
17. Liao W, Huang J, Wu Q, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: a cost-effectiveness analysis. Oral Oncol, 2019, 93: 15-20.
18. Fei Z, Xu T, Li M, et al. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol, 2020, 15(1): 230.
19. Jin C, Zheng H, Zhan M, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol, 2020, 277(2): 577-584.
20. Wu Q, Liao W, Huang J, et al. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma. Oral Oncol, 2020, 103: 104588.
21. Yang J, Han J, He J, et al. Real-world cost-effectiveness analysis of gemcitabine and cisplatin compared to docetaxel and cisplatin plus fluorouracil induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol, 2020, 10: 594756.
22. She L, Tian K, Han J, et al. Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol, 2022, 12: 904372.
23. Tian K, Han J, Wang Z, et al. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis. Oral Oncol, 2022, 128: 105842.
24. Zhu Y, Liu K, Ding D, et al. Chemo-immunotherapy regimes for recurrent or metastatic nasopharyngeal carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol, 2022, 13: 858207.
25. Li G, Xia YF, Huang YX, et al. Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: cost-effectiveness analysis. Head Neck, 2022, 44(2): 431-442.
26. 中国临床肿瘤学会指南工作委员会. 鼻咽癌诊疗指南2022. 北京:人民卫生出版社, 2022, 27: 47, 63, 69.
27. 何朝光, 傅万凯, 陈彩霞, 等. 1990和2017年中国鼻咽癌疾病负担及其趋势. 海峡预防医学杂志, 2020, 26(4): 108-110.
28. 王木清, 江文霞, 张静. 鼻咽癌门诊病例的临床特征及健康教育. 中国医药指南, 2015, 13(4): 17-19.
29. 黄志碧. 广西恶性肿瘤经济负担的现状、变动的趋势及其影响因素的研究. 南宁: 广西医科大学, 2016.

Previous Article
Economic evaluation of anti-novel coronavirus infection drugs: a systematic review
Next Article
Quality evaluation of pharmacoeconomics studies on Chinese patent medicines in neoplasm

Chinese Journal of Evidence-Based Medicine

Health economic evaluation in nasopharyngeal carcinoma: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content